Testing

2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.

David Loew

CEO

– 26 October 2024

YTD 2023 Sales – Updated

– 16 September 2025

Testing video 1

– 16 September 2025

Testing video 3

– 16 September 2025

Testing video 2

30 September 2025

Test Register Events

David Loew

CEO

The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.

Beyond financial achievements, we demonstrated a profound commitment to sustainability through our Generation Ipsen strategy. We achieved a 36% reduction in Scope 1 and 2 emissions and a 29% reduction in Scope 3 emissions, and set ambitious goals to become carbon neutral by 2025 and reach net-zero emissions by 2045.

Our journey in 2023 is a story of transformation, innovation, and unwavering dedication as we Focus. Together. For patients and society.

Discover more about our journey and innovations.

Testing

- 11 June 2024 - 1 mins read

This is dummy text to the Event. Automatically keep track of every email sent from your WordPress site and view valuable statistics right here in your dashboard. This is dummy text to the Event. Automatically keep track of every email sent from your WordPress site and view valuable statistics right here in your dashboard. This is dummy text to the Event. Automatically keep track of every email sent from your WordPress site and view valuable statistics right here in your dashboard. This is dummy text to the Event. Automatically keep track of every email sent from your WordPress site and view valuable statistics right here in your dashboard.